Document Detail


Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MedLine Citation:
PMID:  24287689     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: A recent phase III randomized controlled trial (NCT00434148) showed efficacy of pasireotide in the treatment of patients with Cushing's disease (CD). Patients were invited to participate in an extension phase of the protocol and a subgroup had a sustained response. We report the experience with 4 patients in our center of which 2 full responders have completed 5.5 and 4.25 years of treatment with disease control.
METHODS: The trial protocol was described previously. The extension phase consisted of 3-monthly visits with clinical, biochemical, and imaging evaluation and investigator-driven pasireotide titration. Research charts were retrospectively analyzed.
RESULTS: Four patients with persistent CD following pituitary surgery completed the first 6 months of the trial and 3 continued in the next 6 month open-label phase. Two patients with baseline urinary free cortisol (UFC) 5.3-6.7 times the upper limit of normal had a rapid sustained response to pasireotide and entered the extension phase after 12 months. They remain in clinical and biochemical disease remission and 1 patient now only requires 300 μg daily of pasireotide. All 4 patients developed glucose intolerance; however, the two patients in the extension phase were eventually able to discontinue all diabetes pharmacotherapy. Adverse events included second degree atrioventicular block type 1 without QT prolongation in a patient with pre-existing sinus bradycardia, and symptomatic cholelithiasis requiring cholecystectomy in a second patient.
CONCLUSIONS: Pasireotide therapy can provide normalization of UFC and of clinical symptoms and signs of CD during up to 5 years of follow-up. This study demonstrates the possible recuperation of normoglycemia after continued use of pasireotide and control of underlying hypercortisolemia. Longer-term monitoring for potential adverse events related to continued use of pasireotide is indicated.
Authors:
Jessica Mackenzie Feder; Isabelle Bourdeau; Sophie Vallette; Hugues Beauregard; Louis-Georges Ste-Marie; André Lacroix
Related Documents :
23518619 - Clinical efficacy of botanical extracts from eupatorium adenophorum against the sarcopt...
23453419 - Timing of curative treatment for prostate cancer: a systematic review.
23888339 - The influence of operation technique on long-term results of achalasia treatment.
25106899 - Radiofrequency ablation versus partial nephrectomy for clinical t1b renal cell carcinom...
24398339 - Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe...
23478199 - Ultrasound-guided surgery for palpable breast cancer is cost-saving: results of a cost-...
24619589 - Turoctocog alfa for the treatment of hemophilia a.
19478489 - Prevention of preterm delivery with periodontal treatment.
23602769 - Clinical outcome following stringent discontinuation of dual anti-platelet therapy afte...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-28
Journal Detail:
Title:  Pituitary     Volume:  -     ISSN:  1573-7403     ISO Abbreviation:  Pituitary     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Endocrinology, Department of Medicine and Research Center, Centre Hospitalier de l'Université de Montréal (CHUM)-Hotel-Dieu, 3850 Saint-Urbain Street, Montreal, QC, H2W 1T8, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Azacalix[2]arene[2]triazine-based receptors bearing carboxymethyl pendant arms on nitrogen bridges: ...
Next Document:  The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Grou...